Tag: "niaid" at medical news

NIAID initiates trial of experimental avian flu vaccine

Fast-track recruitment has begun for a trial to investigate the safety of a vaccine against H5N1 avian influenza, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. ...... Sites in Rochester, NY, Baltimore and Los Angeles will enroll a total of 450 healthy adults. The clinical sites are part of the NIAID-sponsored V...

NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed

...... The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the U.S. Army Medical Research and Materiel Command (USAMRMC) of the Department of Defense (DoD), support a broad, comprehensive HIV/AIDS research and development program. Two recent decisions will substantially contribute to a coordinated and comprehensive U.S. governm...

NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks

The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is soliciting applications from U.S. and overseas research institutions seeking to become Clinical Trials Units (CTUs) in the Institute's revamped HIV/AIDS Clinical Trials Networks. NIAID, part of the U.S. National Institutes of Health (NIH), supports the world's largest portfolio of clinical research in HIV...

NIAID begins enrolling volunteers for novel HIV vaccine study

A large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia. Organizers are seeking 1,500 participants....... The trial is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company Merck & Co. Inc. Merck develo...

NIAID-sponsored clinical trial aims to boost flu vaccine supply

In an effort to expand the supply of flu vaccine available in the United States in the future, a clinical trial of an influenza vaccine widely used in Europe has begun recruiting participants at four sites nationwide. Funding for the study comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, which is collaborating with the vaccin...

NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks

The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is restructuring its HIV/AIDS clinical trials networks and soliciting investigators and institutions to lead the reorganized effort. This reorganization, designed in response to both the changing face of the AIDS epidemic and evolving scientific challenges, will enable NIAID and its many collaborators to eff...

NIAID launches influenza genome sequencing project

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced a joint influenza genome sequencing project with several scientific partners. The project will help researchers understand how flu viruses evolve, spread and cause disease. According to its leaders, it has the potential to minimize the impact of annual flu outbreaks...

NIAID launches program to improve medical tools against emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions. The study of these regions, known as epit...

NIAID forms network to tackle potentially fatal reaction to smallpox vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atop...

NIAID rotavirus vaccine licensed for commercialization

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today a new license agreement aimed at helping to prevent hundreds of thousands of deaths annually from rotavirus diarrhea in children living in developing countries. An effective oral rotavirus vaccine--created by NIAID scientists in the mid- to late 1980s and developed f...

Second NIAID SARS vaccine candidate helps mice fend off SARS

An experimental vaccine based on a critical piece of the SARS virus protects mice from SARS infection, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found. When exposed to the SARS virus, immunized mice produced SARS-specific antibodies, and virus replication was nearly eliminated....... The new report, to be pu...

NIAID vaccine protects against SARS virus infection in mice

An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a recently-described mouse model of SARS infect...

NIAID Ebola vaccine enters human trial

The first human trial of a vaccine designed to prevent Ebola infection opened today. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), designed the vaccine, which was administered to a volunteer at the NIH Clinical Center in Bethesda. The vaccine does not contain any infectious ma...

NIAID initiative addresses primary immune deficiency diseases

The study of primary immunodeficiency diseases--disorders caused by inherited flaws in the immune system that increase susceptibility to infections--has been bolstered by a $12.8 million initiative sponsored by the National Institutes of Health (NIH). The initiative establishes the Primary Immunodeficiency Research Consortium (PIRC), a coalition of the world's most prominent researchers in the fi...

NIAID funds construction of biosafety laboratories

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced funding for the construction of two National Biocontainment Laboratories (NBLs) and nine Regional Biocontainment Laboratories (RBLs). "These awards to build high-level biosafety facilities are a major step towards being able to provide Americans with effective therapies, v...

NIAID reports 'tremendous progress' in biodefense research

Biomedical researchers in government, academia and industry have made tremendous progress working collaboratively towards developing countermeasures for bioterrorism, according to a report issued today on research funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. ......The NIAID Biodefense Research Agenda for CDC Category A Agen...

NIAID awards $81 million for HIV vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced four new contracts to support development of candidate HIV vaccines. The awards are part of NIAID's HIV Vaccine Design and Development Teams (HVDDT) program, a public-private partnership that seeks to accelerate HIV vaccine development. The Institute has committed ap...

NIAID launches malaria vaccine trial in Africa

The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, has reached a milestone in its efforts to support accelerated development of malaria vaccines. Working with an international group of public and private partners, NIAID has launched its first trial of a candidate malaria vaccine in a country where malaria is endemic. The Phase I trial, tak...

NIAID opens innovative treatment study for West Nile virus

A clinical trial evaluating an experimental treatment for patients infected with West Nile virus (WNV) has begun enrolling volunteers at 36 sites nationwide, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, announced today. This study is part of a larger effort by NIAID to develop new ways to prevent and treat the disease. ... ..."West N...

NIAID releases 20th anniversary edition of Jordan Report on vaccine research

Vaccines have become an increasingly important medical tool against a variety of public health problems, both in the United States and abroad. To inform policy-makers, researchers and the public about recent accomplishments and future trends in vaccine research, the National Institute of Allergy and Infectious Diseases (NIAID) today released a new edition of its comprehensive vaccine report, The...

NIAID expands vaccine testing network

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded seven new contracts that will expand and reorganize its network of university-based sites conducting clinical trials of promising vaccine candidates and therapies for infectious diseases. The reconfigured Vaccine Treatment and Evaluation Units (VTEUs) will enable NIAID to fund more clinical trials focused on specific po...

NIAID teams with Wyeth on HIV/AIDS vaccine

The National Institute of Allergy and Infectious Diseases (NIAID) today announced the latest contract award in its innovative HIV Vaccine Design and Development Teams (HVDDT) program, a public-private partnership mechanism aimed at accelerating HIV vaccine development. Wyeth Vaccines, a unit of Wyeth Pharmaceuticals, will receive $22.8 million over the next 5 years to expand research on a vaccin...

NIAID study results support diluting smallpox vaccine stockpile to stretch supply

HHS Secretary Tommy G. Thompson today announced that results from a key clinical trial indicate that the existing U.S. supply of smallpox vaccine-15.4 million doses-could successfully be diluted up to five times and retain its potency, effectively expanding the number of individuals it could protect from the contagious disease.... ...The public health implications of this study are enormously imp...

NIAID events highlight global health research

.During two events in May, the National Institute of Allergy and Infectious Diseases (NIAID) will highlight new and ongoing international research efforts in the fight against malaria and other tropical diseases. .On Monday, May 7, NIAID Director Anthony S. Fauci will unveil the Institute's Global Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis. Dr. Fauci will describe the plan du...

NIAID awards major malaria vaccine research contract

...In its continuing efforts to promote research on vaccines to prevent malaria, the National Institute of Allergy and Infectious Diseases (NIAID) recently awarded a seven-year, $43.8 million contract to Science Applications International Corporation (SAIC), McLean, Va., for malaria vaccine production and support services. The contract will support the transition of new malaria vaccine candidat...

NIAID public-private partnerships seek to develop HIV/AIDS vaccine

.The National Institute of Allergy and Infectious Diseases (NIAID) announced today four novel public-private partnerships to accelerate development of promising HIV/AIDS vaccines for use around the world. The new partnerships, called HIV Vaccine Design and Development Teams (HVDDT), tap the different skills and talents of private industry and academic research centers, and provide incentive to...

NIAID funds three Chronic Fatigue Syndrome (CFS) Research Centers

.The National Institute of Allergy and Infectious Diseases (NIAID) today.announced new research awards totaling $1.9 million in first-year funding to.support three Chronic Fatigue Syndrome (CFS) Cooperative Research Centers. The.centers will conduct broadly focused research addressing basic science, clinical.and epidemiological aspects of CFS, including its causes, characteristics and.treatment...

NIAID spearheads collaborative network for clinical research on immune tolerance

.The National Institute of Allergy and Infectious Diseases (NIAID) is.spearheading a $144 million initiative to develop new ways of inducing immune.tolerance -- selectively modulating the immune system by inhibiting harmful.immune responses while keeping protective ones intact. The strategy promises to.improve the success of transplants and treatments for autoimmune diseases that.destroy the bo...

NIAID Renews Funding For Multicenter AIDS Cohort Study

.The National Institute of Allergy and Infectious Diseases (NIAID) has awarded.five-year grants to continue the work of the Multicenter AIDS Cohort Study.(MACS), the largest continually followed group of HIV-infected or at-risk.individuals in the world. Approximately $6 million in first-year funding will.be distributed among MACS research centers at The Johns Hopkins University; the.University...

NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

CHAPEL HILL, N.C. -- The National Institute of Allergy and Infectious Diseases has stopped an .AIDS drug clinical trial early because researchers have found a three-drug "cocktail" including .the protease inhibitor indinavir significantly reduced AIDS symptoms and prolonged patient .survival compared to a combination of two drugs. . Known as AIDS Clinical Trials Group (ACTG) 320, the study was b...
(Date:7/30/2014)... teaching hospital in Ireland has shown than many of them ... minimise the risk of entrapment. The report, published online in ... need for careful selection of patients for whom bedrails are ... and maintenance of hospital bed systems. , Bedrails are commonly ... However, although the risk for any individual is extremely low, ...
(Date:7/30/2014)... July 30, 2014 Victory Medical ... proud to announce the launch of a pediatric unit ... general surgery. The doctors working in the pediatrics departments ... infants, children, and adolescents. Dr. Timothy Cole, Dr. Dale ... McDuffie, Dr. Neelesh Mehendale, and Dr. Nicholas Peiffer lead ...
(Date:7/30/2014)... 30, 2014 Dialogic Inc. ... announced that DollarPhone, the largest privately owned calling ... Dialogic® ControlSwitchâ„¢ softswitch to offer enhanced ... portability (LNP) to both its wholesale and prepaid ... is able to power DollarPhone’s network infrastructure, allowing ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... -- ,Middle-aged adults with a history of alcohol abuse ... develop severe memory problems later in life, according to ... findings could help doctors identify those at risk for ... drinking. "We already know there is an association ... -- that understanding is based on asking older people ...
Breaking Medicine News(10 mins):Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2
Other Tags
genesyschemotherapeuticgemcitabinebluefincommunityhelpedneutralnanofactoriescartographycorticalhorizonsstrongestcompleterecalledeliminationexternal